Auxilium Pharmaceuticals Inc. has added another piece to the expanding global market for Xiaflex (collagenase Clostridium histolyticum) with an agreement that gives Asahi Kasei Pharma Corp., of Tokyo, exclusive rights to commercialize Xiaflex for the treatment of Dupuytren's contracture and Peyronie's disease in Japan.